(IN BRIEF) Researchers from UCSF and the Technical University of Munich (TUM) have developed engineered regulatory immune cells to precisely modulate the immune system, addressing conditions like type 1 diabetes, autoimmune diseases, and organ transplant rejection. Unlike traditional immunosuppressants, this … Read the full press release
Innovation Center project of Merck aims to develop smart neurostimulators for targeted treatment of chronic diseases Second collaboration within the Bioelectronics innovation field of Merck focuses on increasing the selectivity and power efficiency of the device to enable energy intensive … Read the full press release
Posted in Germany, Healthcare, News, Pharma & Biotech, Science, Spain, Technology
Tagged bioelectronic, bioelectronic therapies, bioelectronics, Bioelectronics innovation, Carolina Aguilar, chronic diseases, electronic therapies, endocrine disorders, graphene, graphene electrodes, graphene interfaces, Inbrain Neuroelectronics, inflammatory disorders, Innervia Bioelectronics, Jurriaan Baker, Laura Matz, Merck, metabolic disorders, neuroloop GmbH, neurostimulators, physiological datasets, precise signal coding, Reduced Graphene Oxide, rGO, Robert Spoelgen, selective neurostimulation, start-up, vagus nerve
(PRESS RELEASE) PARIS/ CAMBRIDGE, 11-Jan-2021 — /EuropaWire/ — French multinational pharmaceutical company Sanofi to acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics. The agreement includes an upfront payment … Read the full press release
Posted in France, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged acquisition, antibody for inflammatory disorders, antibody technologies, atopic dermatitis, biopharmaceutical, biopharmaceutical company, EASI, Eczema Area and Severity Index, fully human antibodies, Goodwin PLC, Gotshal & Manges LLP, human monoclonal antibodies, human monoclonal antibody, ICOS agonist monoclonal antibody, immune regulator, immune-mediated diseases, immuno-oncology therapeutics, inflammatory disorders, J.P. Morgan, John Reed M.D. Ph.D., KY1005, KY1044, Kymab, novel therapies, OX40-Ligand, OX40L, Paul Hudson, Sanofi, Simon Sturge, topical corticosteroids, Weil
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?